Holen Sie sich die Stockscreener-App
2.90
0.34%
-0.01
Handel nachbörslich:
2.89
-0.010
-0.34%
Schlusskurs vom Vortag:
$2.91
Offen:
$2.9
24-Stunden-Volumen:
101.29K
Relative Volume:
0.38
Marktkapitalisierung:
$96.80M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-12.48M
KGV:
-7.4359
EPS:
-0.39
Netto-Cashflow:
$-7.93M
1W Leistung:
-4.61%
1M Leistung:
+5.45%
6M Leistung:
-2.36%
1J Leistung:
-1.69%
1-Tages-Spanne:
$2.80
$2.98
1-Wochen-Bereich:
$2.78
$3.02
52-Wochen-Spanne:
$2.331
$5.4566
Anixa Biosciences Inc Stock (ANIX) Company Profile
Firmenname
Anixa Biosciences Inc
Sektor
Branche
Telefon
408-708-9808
Adresse
3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE
Compare ANIX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANIX
Anixa Biosciences Inc
|
2.90 | 97.13M | 0 | -12.48M | -7.93M | -0.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.14 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Anixa Biosciences Inc Stock (ANIX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-21 | Eingeleitet | Maxim Group | Buy |
| 2022-12-23 | Eingeleitet | Chardan Capital Markets | Buy |
| 2021-04-12 | Eingeleitet | H.C. Wainwright | Buy |
Anixa Biosciences Inc Aktie (ANIX) Neueste Nachrichten
ANIX SEC FilingsAnixa Biosciences Inc 10-K, 10-Q, 8-K Forms - Stock Titan
ANIX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Anixa Biosciences to host 2026 annual meeting of stockholders and provide corporate update highlighting recent clinical and regulatory progress - marketscreener.com
Anixa Biosciences To Host 2026 Annual Meeting Of Stockholders And Provide Corporate Update Highlighting Recent Clinical And Regulatory Progress - TradingView
Anixa to outline ovarian CAR-T survival, breast cancer vaccine data - Stock Titan
Anixa Biosciences Inc (NASDAQ:ANIX) Given Average Recommendation of "Hold" by Analysts - MarketBeat
Anixa Biosciences Announces Dr. Jose Conejo-Garcia will Keynote the South Carolina Clinical & Translational Research Institute 2026 Retreat - Investing News Network
Anixa Biosciences Announces Dr. Jose Conejo-Garcia will Keynote - GuruFocus
Anixa Biosciences Announces Execution of Data Transfer Agreement with Cleveland Clinic - Intellectia AI
Can Anixa Biosciences Inc. stock double in the next yearJuly 2025 Weekly Recap & Long Hold Capital Preservation Plans - mfd.ru
ANIX: Robust 2025 Milestones Set the Stage for a Pivotal 2026 - Smartkarma
Anixa Biosciences to Present at the iAccess Alpha Virtual Best I - GuruFocus
Whale Trades: Will Anixa Biosciences Inc. stock reach all time highs in 2025 - mfd.ru
Will Anixa Biosciences Inc. stock reach all time highs in 20252025 Price Targets & Community Consensus Trade Alerts - mfd.ru
Why Anixa Biosciences Inc. stock is seen as undervalued2025 Fundamental Recap & Reliable Breakout Forecasts - mfd.ru
Anixa Biosciences Updates Ovarian Cancer CAR-T Trial Outcomes - Intellectia AI
Aug Momentum: Can Anixa Biosciences Inc maintain its current growth rate2025 Valuation Update & Weekly High Return Stock Forecasts - baoquankhu1.vn
Can Anixa Biosciences Inc. keep up with sector leadersJuly 2025 Sentiment & Risk Managed Investment Entry Signals - mfd.ru
Anixa Biosciences CEO Calls 2026 “Pivotal” as Breast Cancer Vaccine, Ovarian CAR-T Advance - MarketBeat
ANIX: Pivotal data from advanced cancer trials and fiscal discipline set the stage for a transformative 2026 - TradingView
Anixa reports promising survival data in ovarian cancer CAR-T trial - Investing.com Australia
Anixa Biosciences Reports Encouraging Patient Survival Observati - GuruFocus
Why Anixa Biosciences Inc. stock is trending among retail tradersWeekly Trend Recap & Daily Profit Focused Screening - mfd.ru
Anixa Biosciences (ANIX) Reports Positive Data in Ovarian Cancer CAR-T Trial - GuruFocus
Anixa Advances Ovarian Cancer CAR-T With Higher Dosing - TipRanks
Anixa Biosciences reports encouraging patient survival observations in ovarian cancer CAR-T trial - marketscreener.com
Anixa Biosciences Reports Encouraging Patient Survival Observations In Ovarian Cancer Car-T Trial - TradingView
ANIX: Major dose escalation approved after strong survival and safety data in ovarian cancer CAR-T trial - TradingView
Anixa Biosciences Reports Encouraging Data in Ovarian Cancer CAR-T Trial - TradingView
Anixa Biosciences Reports Encouraging Patient Survival Observations in Ovarian Cancer CAR-T Trial; Achieves Regulatory Approval Enabling Major Dose Escalation - PR Newswire
EXCLUSIVE: Anixa Biosciences' Ovarian Cancer Drug Candidate Shows Longer Survival With No Major Safety Issues - Sahm
Here's Why We're Not Too Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Situation - Yahoo Finance
Anixa Biosciences (NASDAQ:ANIX) Lowered to Sell Rating by Wall Street Zen - MarketBeat
ANIX: Analyst Maintains "Buy" Rating and $10 Price Target | ANIX Stock News - GuruFocus
D. Boral Capital Reiterates "Buy" Rating for Anixa Biosciences (NASDAQ:ANIX) - MarketBeat
Anixa Biosciences Secures United States Adopted Names Council Approval of Non-Proprietary Name for its CAR-T Therapy, a Key Step Toward Future Commercialization - BioSpace
Anixa Biosciences Secures United States Adopted Names Council Ap - GuruFocus
Anixa Biosciences (ANIX) CAR-T Therapy Receives USAN Approval - GuruFocus
Market Recap: Can Anixa Biosciences Inc keep up with sector leadersJuly 2025 Final Week & Daily Stock Trend Watchlist - baoquankhu1.vn
Anixa Biosciences Inc (NASDAQ:ANIX) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Insider Buying: Arnold Baskies Acquires Additional Shares of Ani - GuruFocus
Anixa Biosciences (NASDAQ:ANIX) Director Arnold Baskies Acquires 10,000 Shares - MarketBeat
Anixa Biosciences director Baskies buys $30,400 in stock By Investing.com - Investing.com UK
Anixa Biosciences director Baskies buys $30,400 in stock - Investing.com
Anixa Biosciences receives Mexican patent for breast cancer vaccine By Investing.com - Investing.com Australia
Finanzdaten der Anixa Biosciences Inc-Aktie (ANIX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Anixa Biosciences Inc-Aktie (ANIX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Titterton Lewis H jr | Director |
Dec 15 '25 |
Option Exercise |
2.92 |
16,000 |
46,720 |
969,334 |
| KUMAR AMIT | Chief Executive Officer |
Oct 30 '25 |
Option Exercise |
2.92 |
200,000 |
584,000 |
779,925 |
| Titterton Lewis H jr | Director |
Jul 31 '25 |
Buy |
3.08 |
10,000 |
30,800 |
953,334 |
| KUMAR AMIT | Chief Executive Officer |
Jul 30 '25 |
Buy |
3.16 |
5,000 |
15,800 |
579,925 |
| Baskies Arnold M | Director |
Jul 18 '25 |
Buy |
3.39 |
5,000 |
16,950 |
125,000 |
| Titterton Lewis H jr | Director |
Jul 11 '25 |
Buy |
3.14 |
10,000 |
31,400 |
943,334 |
| KUMAR AMIT | Chief Executive Officer |
Jul 11 '25 |
Buy |
3.15 |
5,000 |
15,750 |
574,925 |
| KUMAR AMIT | Chief Executive Officer |
Jun 04 '25 |
Buy |
2.85 |
10,000 |
28,500 |
569,925 |
3.69%
0.71%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):